Zefamenib

• Description:

  Zefamenib (BN-104) is an effective selective brain membrane protein inhibitor with oral activity, and it's also a Menin inhibitor, it can block the Menin-MLL interaction and leads to the degradation of Menin protein. Zefamenib is a weak hERG inhibitor, with an IC50 greater than 100 μM. Zefamenib has anti-tumor activity and can be used in cancer research, such as for acute myeloid leukemia[1].

• Product Name Alternative:

  BN-104; BNM-1192; Menin-MLL inhibitor 27

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain; Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bn-104.html

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@H]1[C@]2([H])[C@](CCC2)([H])CN1)N3CCC4(CC3)CN(C5=NC=NN=C5OC6=C(C7=CN=CN=C7C8CC8)C=C(C=C6)F)C4

• Molecular Formula:

  C31H35FN8O2

• Molecular Weight:

  570.66

• References & Citations:

  [1]Taishan Hu, et al. "Discovery of a novel menin-MLL inhibitor for potential treatment of MLLr leukemias and NPM1c AML." Cancer Research. Vol. 82. No. 12. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2022.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  2938995-50-5